会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 16. 发明专利
    • Extended recombinant polypeptides and compositions comprising same
    • NZ628987A
    • 2015-11-27
    • NZ62898710
    • 2010-02-03
    • AMUNIX OPERATING INC
    • SCHELLENBERGER VOLKERCLELAND JEFFREY LSILVERMAN JOSHUASTEMMER WILLEM PWANG CHIA-WEIGEETHING NATHANTO WAYNESPINK BENJAMIN
    • C07K1/00C07K14/00C07K17/00
    • Disclosed is an syringe or a kit comprising a pharmaceutical compositions comprising an extended recombinant polypeptide (XTEN) comprising greater than about 36 to about 3000 amino acid residues, wherein the XTEN is characterized in that: (a) the sum of glycine (G), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P) residues constitutes more than about 80% of the total amino acid sequence of the XTEN; (b) the XTEN sequence is substantially non-repetitivesuch that (i) the XTEN contains no three contiguous amino acids that are identical unless the amino acids are serine; (ii) at least about 80% of the XTEN sequence consists of non-overlapping sequence motifs, each of the sequence motifs comprising about 9 to about 14 amino acid residues consisting of four to six types of amino acids selected from glycine (G), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P), wherein any two contiguous amino acid residues do not occur more than twice in each of the non-overlapping sequence motifs; or (iii) the XTEN sequence has a subsequence score of less than 10; (c) the XTEN sequence lacks a predicted T-cell epitope when analyzed by TEPITOPE algorithm, wherein the TEPITOPE algorithm prediction for epitopes within the XTEN sequence is based on a score of –9 or greater. (d) the XTEN sequence has greater than 90% random coil formation as determined by GOR algorithm; and (e) the XTEN sequence has less than 2% alpha helices and 2% beta-sheets as determined by Chou-Fasman algorithm.